DiaMedica Therapeutics appoints Daniel J. O'Connor to Board of Directors

DiaMedica Therapeutics Inc.

Daniel J. O'Connor appointed to Board effective Feb 20, 2025; joins Audit and Nominating & Corporate Governance Committees.
O'Connor previously served as CEO of Ambrx Biopharma, guiding it from $40M valuation to $2B acquisition by Johnson & Johnson in 14 months.
He received option to purchase 64,242 common shares at fair market value, vesting quarterly over three years.
Initial equity award for non-employee directors increased from 0.12% to 0.15% of outstanding common shares.
Non-employee director annual equity award also increased from 0.06% to 0.075% of outstanding common shares.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Daniel J. O'Connor

Director

DMAC · DiaMedica Therapeutics Inc.

Effective: 2025-02-20
Filed: February 24, 2025, 6:59 PM ET

On February 20, 2025, the Board of Directors (the “Board”) of DiaMedica Therapeutics Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Daniel J. O’Connor to the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Daniel J. O'Connor was appointed as Director at DiaMedica Therapeutics Inc..

Action: appointed
Role: Director

Exact text from the filing

On February 20, 2025, the Board of Directors (the “Board”) of DiaMedica Therapeutics Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Daniel J. O’Connor to the Board, effective immediately.

View on SEC.gov

DiaMedica Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001437749-25-004891

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.